Dermal Cell News 4.31 September 17, 2018 | |
| |
TOP STORYInvestigators revealed that two neo-antigen-specific clonotypes killed 90% of autologous melanoma cells, both in vitro and in vivo, showing that a limited set of neo-antigen-specific T-cells may play a central role in melanoma tumor rejection. [Cancer Discov] Abstract | Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DERMAL STEM CELLS & TISSUE REGENERATIONSingle Cell and Open Chromatin Analysis Reveals Molecular Origin of Epidermal Cells of the Skin Deletion of β-catenin in Krt8+ progenitors delayed their maturation into Krt5+ progenitors. The lack of epidermal Wnt production in the absence of ΔNp63 also incapacitated Wnt activation in the underlying dermal cells. [Dev Cell] Full Article | Press Release | Graphical Abstract Inhibition of retinoic acid-inducible gene (RIG-I) using small interfering RNA resulted in increased viral gene expression and reduced induction of IFNs and IFN-stimulated genes. Zika virus (ZIKV) non-structural protein 1 directly interacted with RIG-I or melanoma differentiation-associated gene 5 and downregulated RIG-I-like receptor-mediated antiviral signaling pathways. [J Invest Dermatol] Abstract Investigators suggest that a single exposure to perfluorooctanoic acid caused concentration-dependent changes in cell proliferation that were not restored during a 48-hour recovery period. They demonstrated that a moderate treatment with this perfluorochemical caused persistent DNA damage, which ultimately led to development of the senescence-associated secretory phenotype in HaCaT cells. [Food Chem Toxicol] Abstract | Graphical Abstract ROS-Challenged Keratinocytes as a New Model for Oxidative Stress-Mediated Skin Diseases The effects of the reactive oxygen species (ROS) generator 2,2′-azobis(2-amidinopropane) dihydrochloride on extracellular and intracellular ROS production in human keratinocytes were studied. [J Cell Biochem] Abstract SKIN CANCERS & DISORDERSTargeting the Warburg Effect via LDHA Inhibition Engages ATF4 Signaling for Cancer Cell Survival The authors showed that lactate dehydrogenase A (LDHA) activity supported serine and aspartate biosynthesis. Surprisingly, however, LDHA inhibition failed to impact human melanoma cell proliferation, survival, or tumor growth. Reduced intracellular serine and aspartate following LDHA inhibition engaged GCN2-ATF4 signaling to initiate an expansive pro-survival response. [EMBO J] Abstract | Press Release | Graphical Abstract Scientists found that melanoma cells, which developed resistance towards MAPK signaling pathway inhibitors showed an enhanced susceptibility to platinum-based drugs, such as cisplatin and carboplatin. They found that this enhanced susceptibility inversely correlated with the expression level of the p53 family member TAp73. [Cell Death Dis] Full Article In vitro, overexpression of miR-4633-5p suppressed the growth and invasiveness of melanoma cells through inhibiting activation of Akt pathway and secretion of MMP2, while knockdown of miR-4633-5p reversed the inhibitory effects. [Cell Physiol Biochem] Full Article Like WNT agonists, vitamin D significantly inhibited reactive oxygen species accumulation and cell apoptosis in H2O2-treated melanocytes and promoted their proliferative and migratory activity, while the protective effects of vitamin D against oxidative stress were abolished by β-catenin silencing in melanocytes. [Lab Invest] Abstract Researchers illustrated that let-7b promoted differentiation of keratinocytes in vivo and in vitro. They found that IL-6 was a target gene of let-7b. In psoriasis, high expression levels of IL-6 led to increased acivation of p-ERK1/2. [Cell Commun Signal] Full Article Subscribe to one of our other 19 science newsletters such as Extracellular Matrix News & Cancer Stem Cell News. | |
| |
REVIEWSMucosal and Skin Langerhans Cells – Nurture Calls Recent studies have demonstrated that murine langerhans cells (LCs) in mucosal epithelia arise and are continuously replenished from circulating bone marrow precursors. This has led to the emergence of a novel perspective proposing that LCs can evolve from various origins. [Trends Immunol] Abstract Visit our reviews page to see a complete list of reviews in the dermal cell research field. | |
| |
SCIENCE NEWSEli Lilly and Company announced that it will present new data for Taltz®, Olumiant® and mirikizumab. [Press release from Eli Lilly and Company discussing research presented at the 27th Annual European Academy of Dermatology and Venereology (EADV) Congress, Paris] Press Release Bristol-Myers Squibb Company announced results from a Phase II study of BMS-986165, an investigational oral, selective tyrosine kinase 2 inhibitor, in patients with moderate to severe plaque psoriasis. [Press release from Bristol-Myers Squibb Company discussing research presented at the 27th Annual European Academy of Dermatology and Venereology (EADV) Congress, Paris] Press Release AbbVie announced new results from the ongoing Phase IIb study including longer-term efficacy and safety data and patient-reported outcomes data evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe atopic dermatitis. [Press release from AbbVie discussing research presented at the 27th Annual European Academy of Dermatology and Venereology (EADV) Congress, Paris] Press Release Detailed results from a pivotal Phase III trial showed Dupixent® monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. [Press release from Sanofi discussing research presented at the 27th Annual European Academy of Dermatology and Venereology (EADV) Congress, Paris] Press Release | |
| |
INDUSTRY NEWSArQule, Inc. announced that the U.S. FDA has granted Fast Track Designation to miransertib for the treatment of PROS, a group of related, ultra-rare genetic disorders characterized by excessive tissue growth in various parts of the body. [Arqule] Press Release Eli Lilly and Company announced the initiation of the IXORA-R head-to-head (H2H) clinical trial, designed to evaluate superiority between Taltz® and Tremfya® in adult patients with moderate-to-severe plaque psoriasis. The IXORA-R study will be the first H2H trial between an IL-17 and IL-23 using the Psoriasis Area Severity Index 100 score as the primary endpoint. [Eli Lilly and Company.] Press Release Novartis, announced new data from multiple real-world sources in moderate-to-severe plaque psoriasis, which confirm Cosentyx® efficacy and safety in clinical practice is comparable to previously reported clinical studies. [Novartis AG] Press Release The Jackson Laboratory (JAX) and Azitra, Inc. have been awarded a $500,000 grant from the Department of Defense. The goal of the program is to identify bioactive compounds produced by Staphylococcus epidermidis that can inhibit Staphylococcus aureus and ultimately treat skin infections. [The Jackson Laboratory] Press Release | |
| |
POLICY NEWSJudge Dismisses Criminal Charges against US University Chemist Over Lab Death A judge in Los Angeles county has dismissed a criminal case against chemist Patrick Harran, who faced charges of violating health and safety standards after an accidental death in his laboratory nine years ago. The charges stemmed from a 2009 incident in which Sheharbano Sangji, a research assistant in Harran’s lab at the University of California, Los Angeles, died from third-degree burns incurred during a chemical fire. [Nature News] Editorial Evidence-Based Medicine Group in Turmoil after Expulsion of Co-Founder A bitter dispute with one of its co-founders has plunged Cochrane, an international network of scientists promoting evidence-based medicine, into a crisis on the eve of an international gathering that marks its 25th anniversary. A narrow majority of the organization’s Governing Board apparently decided to end the Cochrane membership of Peter Gøtzsche, director of the Nordic Cochrane Centre in Copenhagen and a member of the board himself, for causing “disrepute” to the organization. Four other board members then resigned in protest. [ScienceInsider] Editorial Patients vs. Paywalls: Is the U.S. Ready for Open-Access Publishing? Scientific publishing giant Elsevier recently came under fire after its director of scholarly communications, William Gunn, wrote a controversial tweet in response to a post that “people shouldn’t have to jump through hoops” to access important medical research. [STAT News] Editorial NIH Gets $2 Billion Boost in Final 2019 Spending Bill Congress has approved a $2 billion raise, to $39.1 billion, for the National Institutes of Health (NIH) in a 2019 spending bill approved by House of Representatives and Senate negotiators. [ScienceInsider] Editorial
| |
EVENTSNEW AACR: Melanoma: From Biology to Target Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Group Leader – Organoid Modeling of Disease (European Molecular Laboratory) NEW Assistant Professor – Department of Biomedical Engineering (Boston University) Associate Researcher – Inflammatory Skin Diseases (Icahn School of Medicine at Mount Sinai) Postdoctoral Fellow – Skin Cancer (Stanford University School of Medicine) Post-doctoral Positions – Cancer Genetics/Genomics (University of Pennsylvania) Associate Professor or Professor – Skin Cancer (The University of Texas M.D. Anderson Cancer Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Dermal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|